Stock Events

Stock Events

NewAmsterdam Pharma Company NV 

€21.90
19
+€0.13+0.6% 06:01 Today

Statistics

Day High
21.9
Day Low
21.9
52W High
35.4
52W Low
20.8
Volume
-
Avg. Volume
-
Mkt Cap
2.62B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q4 2025
Q1 2026
Q2 2026
Next
-0.53
-0.47
-0.4
-0.34
Expected EPS
-0.4258789986
Actual EPS
N/A

Financials

-913.71%Profit Margin
Unprofitable
2023
2024
2025
19.31MRevenue
-176.45MNet Income

Analyst Ratings

37.94Average Price Target
The highest estimate is 37.94.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow KH6.MU. It's not an investment recommendation.
Microsoft
4
MSFT
NVIDIA
3
NVDA
SoFi Technologies
3
SOFI
Apple
2
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap233.78B
Amgen Inc. develops and produces medications in similar therapeutic areas, including cardiovascular diseases, which directly competes with NewAmsterdam Pharma's focus.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, Inc. is known for its innovation in biopharmaceuticals, particularly in the cardiovascular and metabolic disease areas, overlapping with NewAmsterdam Pharma's market.
Novo Nordisk
NVO
Mkt Cap201.64B
Novo Nordisk A/S specializes in diabetes care but also has a growing presence in the cardiovascular disease sector, competing in the same therapeutic area as NewAmsterdam Pharma.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. offers a broad range of health solutions, including treatments for cardiovascular diseases, which pits it against NewAmsterdam Pharma in market share battles.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc. has a diverse portfolio that includes cardiovascular disease treatments, directly competing with NewAmsterdam Pharma's product offerings.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca PLC has a strong focus on cardiovascular, renal, and metabolism medication, directly aligning with NewAmsterdam Pharma's core areas.
Sanofi
SNY
Mkt Cap107.39B
Sanofi focuses on cardiovascular diseases among other areas, and its broad international reach and established products make it a significant competitor.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly and Company, while primarily known for diabetes care, also ventures into cardiovascular health, competing in the same space as NewAmsterdam Pharma.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol-Myers Squibb Company offers a range of biopharmaceutical products, including those for cardiovascular diseases, competing with NewAmsterdam Pharma.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline plc engages in the creation and marketing of pharmaceutical products, including those for cardiovascular diseases, overlapping with NewAmsterdam Pharma's interests.

About

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
Show more...
CEO
Michael Davidson
Employees
100
Country
Netherlands
ISIN
NL00150012L7
WKN
000A3DUAC

Listings

STU
DE
KH6.STU
MU
DE
KH6.MU
XNAS
US
NAMS
XNAS
US
NAMSW

0 Comments

Share your thoughts

FAQ

What is NewAmsterdam Pharma Company NV stock price today?▼
The current price of KH6.MU is €21.90 EUR — it has increased by +0.6% in the past 24 hours. Watch NewAmsterdam Pharma Company NV stock price performance more closely on the chart.
What is NewAmsterdam Pharma Company NV stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange NewAmsterdam Pharma Company NV stocks are traded under the ticker KH6.MU.
Is NewAmsterdam Pharma Company NV stock price growing?▼
KH6.MU stock has fallen by -6.05% compared to the previous week, the month change is a -10.17% fall, over the last year NewAmsterdam Pharma Company NV has showed a +3.3% increase.
What is NewAmsterdam Pharma Company NV market cap?▼
Today NewAmsterdam Pharma Company NV has the market capitalization of 2.62B
When is the next NewAmsterdam Pharma Company NV earnings date?▼
NewAmsterdam Pharma Company NV is going to release the next earnings report on November 11, 2026.
What were NewAmsterdam Pharma Company NV earnings last quarter?▼
KH6.MU earnings for the last quarter are -0.45 EUR per share, whereas the estimation was -0.42 EUR resulting in a -7.9% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is NewAmsterdam Pharma Company NV revenue for the last year?▼
NewAmsterdam Pharma Company NV revenue for the last year amounts to 19.31M EUR.
What is NewAmsterdam Pharma Company NV net income for the last year?▼
KH6.MU net income for the last year is -176.45M EUR.
How many employees does NewAmsterdam Pharma Company NV have?▼
As of September 04, 2026, the company has 100 employees.
In which sector is NewAmsterdam Pharma Company NV located?▼
NewAmsterdam Pharma Company NV operates in the Health & Wellness sector.
When did NewAmsterdam Pharma Company NV complete a stock split?▼
NewAmsterdam Pharma Company NV has not had any recent stock splits.
Where is NewAmsterdam Pharma Company NV headquartered?▼
NewAmsterdam Pharma Company NV is headquartered in NARRDEN, Netherlands.